Explores bacterial differences affecting glucocorticoid outcomes in chronic rhinosinusitis subgroups, indicating treatment implications.
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) exhibits distinct bacterial colonization patterns between eosinophilic (ECRSwNP) and non-eosinophilic (non-ECRSwNP) subgroups. It remains unclear to what extent these differences are clinically relevant to the response to glucocorticoid (GC) treatment. Objective: This study aimed to investigate differences in nasal bacterial colonization between ECRSwNP and non-ECRSwNP patients in relation to their GC treatment response. Methods: We enrolled 347 CRSwNP patients, including 222 ECRSwNP and 125 non-ECRSwNP patients. Nasal swabs were collected from all participants, and bacterial composition was assessed via standard culture techniques. Of these, 189 patients received a 2-week course of oral GC treatment (24 mg of methylprednisolone daily), and nasal bacterial colonization was analyzed in relation to GC treatment response. Results: Of the 347 CRSwNP patients recruited, Staphylococcus was the most prevalent bacterial genus, followed by Corynebacterium and Streptococcus . Compared to ECRSwNP patients, non-ECRSwNP patients exhibited higher colonization rates of Streptococcus viridans and Haemophilus influenzae , and lower colonization rates of Klebsiella . Among the 189 patients who received GC treatment, further subgroup analysis was performed based on GC sensitivity. In GC-sensitive patients, S. viridans and H. influenzae were significantly more prevalent in non-ECRSwNP than in ECRSwNP. Conversely, among GC-resistant patients, Corynebacterium pseudodiphtheriticum was increased considerably in ECRSwNP than in non-ECRSwNP. Conclusion: Our findings indicate that there are distinct bacterial compositions in non-ECRSwNP and ECRSwNP patients. Streptococcus viridans and H. influenzae are linked to GC-sensitive non-ECRSwNP, while C. pseudodiphtheriticum is associated with GC resistance in ECRSwNP, highlighting their potential role in modulating GC treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: